Summary Company Announcement Date: December 17, 2018 FDA Publish Date: December 17, 2018 Product Type: Food & Beverages Reason for Announcement: Company Name: Atherstone Foods Inc. Brand Name: Brand Name(s) Greens & Grains Product Description: Product Description Hummus and Quinoa Tabouleh Wrap Company Announcement ATHERSTONE FOODS INC of Richmond, CA is recalling 14.6 ounce (414g)…
FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia
FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia. Dr. Sanjeeve Bala: Welcome back to the DISCO, the FDA’s Soundcast in Clinical Oncology from the Oncology Center of Excellence. We are coming to you from Silver Spring, MD, and during…
Recall of Bittersweet & Feve Chocolate Bars Due to High Levels of Milk Allergens
Summary Company Announcement Date: November 09, 2018 FDA Publish Date: November 09, 2018 Product Type: Food & BeveragesMilk/Milk ProductAllergens Reason for Announcement: Company Name: Recchiuti Confections Brand Name: Brand Name(s) Product Description: Product Description Bittersweet and Feve chocolate bars Company Announcement Recchiuti Confections (San Francisco, CA) discovered two batches of their Bittersweet Chocolate Bar and…
A Tattoo for You? Seven Key Questions to Consider
The FDA issued a Safety Advisory on May 15, 2019 warning consumers, tattoo artists, and retailers about using or selling certain tattoo inks contaminated with microorganisms. Español There are many tattooed Americans. Surveys estimate that about one in five Americans now has at least one. And with the rising popularity of tattoos, the U.S. Food…
Snyder’s Lance Announces Voluntary Recall of a Limited Amount of 6.5 oz Emerald® Glazed Walnuts Due to Potential Presence of Undeclared Peanuts, Almonds, Cashews and Pecans
Summary Company Announcement Date: February 21, 2018 FDA Publish Date: June 06, 2019 Product Type: Food & BeveragesAllergensFood & Beverage Safety Reason for Announcement: Company Name: Snyder’s-Lance, Inc. Brand Name: Brand Name(s) Product Description: Product Description Glazed Walnuts Company Announcement Emerald® Nuts is initiating a voluntary recall for a limited amount of its 6.5oz Glazed…
FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma
FDA medical oncologists discuss the September 28, 2018, approval of cemiplimab-rwlc for the treatment of select patients with cutaneous squamous cell carcinoma. Dr. Sanjeeve Bala: Welcome back to the DISCO, the FDA’s Soundcast in Clinical Oncology from the Oncology Center of Excellence. We are coming to you from Silver Spring, MD and during our soundcasts,…
Think Before You Ink: Are Tattoos Safe?
The FDA issued a Safety Advisory on May 15, 2019 warning consumers, tattoo artists, and retailers about using or selling certain tattoo inks contaminated with microorganisms. Español Tattoos are more popular than ever. According to a 2015 Harris Poll, about 3 in 10 (or 29%) people surveyed have at least one tattoo. The U.S. Food…
Ottogi America, Inc. Issues Allergy Alert On Undeclared Egg In Product
Summary Company Announcement Date: November 23, 2018 FDA Publish Date: June 06, 2019 Product Type: Food & BeveragesMeal Replacements Reason for Announcement: Company Name: Ottogi America, Inc. Brand Name: Brand Name(s) Product Description: Product Description Company Announcement Ottogi America, Inc. of Gardena, California announced today it is recalling 1lb 5.16ounce of Jin Ramen Mild 5pk….
Los investigadores de la FDA logran avances científicos en las vacunas para prevenir las paperas y la tosferina
El Dr. Steven A. Rubin, PhD, trabaja con un matraz de células inoculadas con el virus de las paperas en los laboratorios de la FDA en Silver Spring, Maryland. English Subscríbase para recibir artículos para el consumidor en español por email. En una colección de pequeños recipientes de un bien iluminado laboratorio de la Administración…
FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion
FDA medical oncologists discuss the Nov. 26, 2018, accelerated approval of larotrectinib for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no…